Home Health Care Professionals Products

IODOSORB Global

IODOSORB◊ Linea di medicazioni a base di cadexomero iodico allo 0,9%

La composizione a duplice azione offre un’attività antimicrobica ad ampio spettro1,2 con rimozione del tessuto necrotico3,4 ed elevate proprietà di gestione dei liquidi,5-7 il che rende questo prodotto efficace, in vitro e in vivo,8-18 contro i biofilm delle ferite croniche.

840x840-PX-IODOSORB-Global.png

Preparare per progredire

La tecnologia delle microsfere intelligenti viene integrata con iodio elementare allo 0,9% per assicurare un rilascio sostenuto una volta a contatto con i liquidi della ferita.19-21

Soluzione disponibile in forma di unguento IODOSORB, polvere IODOSORB e medicazioni IODOFLEX.*

Caratteristiche del prodotto

Evidence and Case Studies

No Results Message
No Results Message

Customer information

*Controllare la disponibilità di ogni prodotto della linea IODOSORB nel proprio Paese o regione.

Citations
  1. Smith + Nephew 2018.Antimicrobial activity of IODOSORB range against a broad spectrum of wound pathogens. Internal Report. 1801001.
  2. Smith & Nephew 2018.Antimicrobial activity of IODOSORB range in a 3 day repeat challenge model. Internal Report. 1801002.
  3. Hansson C, Persson L-M, Stenquist B, et al. The effects of cadexomer iodine paste in the treatment of venous leg ulcers compared with hydrocolloid dressing and paraffin gauze dressing. International Journal of Dermatology. 1998;37(390-396).
  4. Smith + Nephew 2007.An evaluation of the use of IODOSORB ointment and dressing in the management of chronic exuding wounds. Internal Report. SR/CE/027/IOD.
  5. Smith + Nephew 2017.Review of Perstorp Pharma Absorption Capacity Quality Assurance Data for IODOSORB/IODOFLEX Dressings. Internal Report. DS/17/365/R.
  6. Smith + Nephew 2017.Review of Perstorp Pharma Absorption Capacity Quality Assurance Data for IODOSORB Powder. Internal Report. DS/17/363/R.
  7. Smith + Nephew 2017.Review of Perstorp Pharma Absorption Capacity Quality Assurance Data for IODOSORB Ointment/Gel. DS/17/364/R.
  8. Fitzgerald DJ, Renick PJ, Forrest EC, et al. Cadexomer iodine provides superior efficacy against bacterial wound biofilms in vitro and in vivo. Wound Repair Regen. 2017;25(1):13-24.
  9. Smith & Nephew 2008.IODOFLEX dressings - disruption of a variety of micro-organisms grown in pre-established single and mixed species biofilms. Internal Report. 0804007.
  10. Roche ED, Woodmansey EJ, Yang Q, et al. Cadexomer iodine effectively reduces bacterial biofilm in porcine wounds ex vivo and in vivo. Int Wound J. 2019;1-10 [in press].
  11. Phillips PL, Yang Q, Davis S, et al. Antimicrobial dressing efficacy against mature Pseudomonas aeruginosa biofilm on porcine skin explants. Int Wound J. 2015;12(4):469-483.
  12. Schultz G, Qingpin Y. Microbicidal Effedts of Three Daily Treatments of a Carboxymethylcellulose Silver Dressing or a Cadexomer Iodine on Mature Bactericidal Biofilms Grown on Pig Skin Explants. 2016; Florence.
  13. Schultz G, Bjarnsholt T, James GA, et al. Consensus guidelines for the identification and treatment of biofilms in chronic nonhealing wounds. Wound Repair Regen. 2017;25(5):744-757.
  14. Lantis J.C. Cadexomer Iodine on a biofilm in diabetic foot ulcers: A Pilot study. Paper presented at: WUWHS; 2016; Florence.
  15. Oates JL, Phillips CD, Wolcott R, Woodmansey E. Effect of a Cadexomer Iodine Wound Dressing on a Chronic Wound Multi-Species Biofilm Model with Comparison to a Silver Hydrofiber Antibiofilm Dressing. Paper presented at: SAWC; 2016; Las Vegas, USA.
  16. Malone M, Johani K, Jensen SO, et al. Effect of cadexomer iodine on the microbial load and diversity of chronic non-healing diabetic foot ulcers complicated by biofilm in vivo. J Antimicrob Chemother. 2017;72(7):2093-2101.
  17. Forrest EC, Gunning P, Coleman D, Fitzgerald DJ. Cadexomer Iodine delivers rapid and sustained broad spectrum antimicrobial activity and substantial biofilm disruption and kill in a clinicall revelant wound model. Paper presented at: EWMA; 2019; Gothenburg, Sweden.
  18. Akiyama H, Oono T, Saito M, Iwatsuki K. Assessment of Cadexomer Iodine against Staphylococcus aureus Biofilm In vivo and In vitro Using Confocal Laset Scanning Microscopy. The Journal of Dermatology. 2004;31:529-534.
  19. Hesler B. Release of iodine from IODOSORB/IODOFLEX Dressing into 0.9% saline solution over a three day period. Smith&Nephew Data on File # DS.18.026.R. (2018).
  20. Hesler B. Release of iodine from IODOSORB Powder into 0.9% saline solution over a three day period. Smith&Nephew Data on File # DS.18.024.R. (2018).
  21. Hesler B. Release of iodine from IODOSORB Ointment into 0.9% saline solution over a three day period. Smith&Nephew Data on File # DS.18.025.R. (2018).
  22. Ormiston MC, Seymour MTJ, Venn GE, Cohen RI, Fox JA. Controlled trial of Iodosorb in chronic venous ulcers. British Medical Journal. 1985;291:308-310.
  23. Troeng T, Skog E, Arnesjo B, et al. A Randomised Multicentre Trial to Compare the Efficacy of Cadexomer Iodine and Standard Treatment in the Management of Chronic Venous Ulcers in Out-Patients. Stuttgart: Schattauer Verlag; 1983.
  24. Holloway GA, Johansen KH, Barnes RW, Pierce GE. Multicenter Trial of Cadexomer Iodine to Treat Venous Stasis Ulcer. The Western Journal of Medicine. 1989;151(1):35-38.
  25. Smith + Nephew 2017.IODOSORB Powder Wound Model Testing - 3 day cavity testing with ALLEVYN Gentle Border secondary dressing using horse serum at a flow rate modelling that of a moderately exuding wound. Internal Report. DS/17/249/R.
  26. Smith + Nephew 2017.IODOSORB Ointment / Gel Wound Model Testing - 3 day cavity testing with ALLEVYN Gentle Border secondary dressing using horse serum at a low rate modelling that of a moderately exuding wound. Internal Report. DS/17/572/R.
  27. Smith + Nephew 2017.IODOSORB / IODOFLEX Dressing Wound Model Testing - 3 day cavity testing with ALLEVYN Gentle Border secondary dressing using horse serum at a low rate modelling that of a moderately exuding wound. Internal Report. DS/17/247/R.

Title

Text

Explore